Why the study?
Does chronic antiplatelet therapy before hospitalization impact ischemic and bleeding events in invasively managed patients with acute coronary syndromes?
Does chronic antiplatelet therapy before hospitalization impact ischemic and bleeding events in invasively managed patients with acute coronary syndromes?
Prior chronic antiplatelet therapy, particularly dual antiplatelet therapy, predicts worse 1-year ischemic outcomes in invasively managed ACS patients, despite no increased risk at 30 days.
Contrary to earlier studies, prior antiplatelet therapy was not associated with an increased risk of adverse outcomes at 30 days in invasively managed patients. Such use did, however, independently predict 1-year ischemic MACE, with outcomes worse for patients presenting on chronic dual antiplatelet therapy compared with aspirin alone.
No takes yet. Share an insight, caveat, or question.
Ambrosio et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: